URGN
Income statement / Annual
Last year (2023), UroGen Pharma Ltd.'s total revenue was $82.71 M,
an increase of 28.52% from the previous year.
In 2023, UroGen Pharma Ltd.'s net income was -$102.24 M.
See UroGen Pharma Ltd.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$82.71 M
|
$64.36 M
|
$48.04 M
|
$11.80 M
|
$18,000.00
|
$1.13 M
|
$8.16 M
|
$17.53 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$9.36 M |
$7.65 M |
$5.16 M |
$1.01 M |
$0.00 |
$1.80 M |
$600,000.00 |
$28,000.00 |
$113,000.00 |
$0.00 |
| Gross Profit |
$73.35 M |
$56.70 M |
$42.89 M |
$10.79 M |
$18,000.00 |
-$675,000.00 |
$7.56 M |
$17.50 M |
-$113,000.00 |
$0.00 |
| Gross Profit Ratio |
0.89 |
0.88 |
0.89 |
0.91 |
1 |
-0.6 |
0.93 |
1 |
0 |
0 |
| Research and Development
Expenses |
$45.61 M
|
$52.91 M
|
$47.64 M
|
$47.31 M
|
$49.30 M
|
$36.93 M
|
$18.70 M
|
$10.29 M
|
$10.52 M
|
$4.01 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$60.20 M
|
$39.57 M
|
$8.81 M
|
$6.42 M
|
$1.90 M
|
$890,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$93.27 M
|
$82.84 M
|
$87.54 M
|
$90.22 M
|
$60.20 M
|
$39.57 M
|
$8.81 M
|
$6.42 M
|
$1.90 M
|
$890,000.00
|
| Other Expenses |
$0.00 |
$72,000.00 |
$0.00 |
$0.00 |
-$284,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$138.89 M |
$135.74 M |
$135.18 M |
$137.53 M |
$109.50 M |
$76.51 M |
$27.51 M |
$16.70 M |
$12.41 M |
$4.36 M |
| Cost And Expenses |
$148.25 M |
$143.40 M |
$140.33 M |
$138.54 M |
$109.50 M |
$78.31 M |
$28.11 M |
$16.73 M |
$12.41 M |
$4.36 M |
| Interest Income |
$2.64 M |
$1.01 M |
$212,000.00 |
$1.63 M |
$4.62 M |
$1.87 M |
$0.00 |
$1,000.00 |
$0.00 |
$120,000.00 |
| Interest Expense |
$14.72 M |
$8.44 M |
$17.44 M |
$357,000.00 |
$284,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.71 M
|
$1.82 M
|
$1.77 M
|
$2.04 M
|
$1.32 M
|
$417,000.00
|
$207,000.00
|
$213,000.00
|
$113,000.00
|
$30,000.00
|
| EBITDA |
-$63.83 M
|
-$78.03 M
|
-$90.15 M
|
-$122.71 M
|
-$108.15 M
|
-$77.18 M
|
-$19.74 M
|
$1.01 M
|
-$12.30 M
|
-$4.34 M
|
| EBITDA Ratio |
-0.77 |
-1.21 |
-1.56 |
-10.74 |
-6008.56 |
-68.42 |
-2.45 |
0.06 |
0 |
0 |
| Operating Income Ratio
|
-0.79
|
-1.23
|
-1.92
|
-10.74
|
-6082.11
|
-68.42
|
-2.45
|
0.05
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$32.79 M
|
-$28.99 M
|
-$17.08 M
|
$1.63 M
|
$4.33 M
|
$1.65 M
|
-$31,000.00
|
-$2.74 M
|
-$279,000.00
|
-$107,000.00
|
| Income Before Tax |
-$98.32 M |
-$108.03 M |
-$109.37 M |
-$125.11 M |
-$105.15 M |
-$75.53 M |
-$19.98 M |
-$1.94 M |
-$12.69 M |
-$4.48 M |
| Income Before Tax Ratio
|
-1.19
|
-1.68
|
-2.28
|
-10.6
|
-5841.44
|
-66.96
|
-2.45
|
-0.11
|
0
|
0
|
| Income Tax Expense |
$3.92 M |
$1.14 M |
$1.45 M |
$3.37 M |
-$4.62 M |
$125,000.00 |
$19,000.00 |
$0.00 |
$0.00 |
$81,000.00 |
| Net Income |
-$102.24 M |
-$109.16 M |
-$110.82 M |
-$128.48 M |
-$100.53 M |
-$75.66 M |
-$20.00 M |
-$1.94 M |
-$12.69 M |
-$4.56 M |
| Net Income Ratio |
-1.24 |
-1.7 |
-2.31 |
-10.89 |
-5585 |
-67.07 |
-2.45 |
-0.11 |
0 |
0 |
| EPS |
-3.55 |
-4.79 |
-4.96 |
-5.9 |
-4.9 |
-4.8 |
-2.06 |
-0.16 |
-5.51 |
-1.98 |
| EPS Diluted |
-3.55 |
-4.79 |
-4.96 |
-5.9 |
-4.9 |
-4.8 |
-2.06 |
-0.16 |
-5.51 |
-1.98 |
| Weighted Average Shares
Out |
$28.83 M
|
$22.81 M
|
$22.35 M
|
$21.78 M
|
$20.53 M
|
$15.75 M
|
$9.72 M
|
$11.97 M
|
$2.30 M
|
$2.30 M
|
| Weighted Average Shares
Out Diluted |
$28.83 M
|
$22.81 M
|
$22.35 M
|
$21.78 M
|
$20.53 M
|
$15.75 M
|
$9.72 M
|
$11.97 M
|
$2.30 M
|
$2.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
